表紙
市場調査レポート

体外受精サービスのアジア太平洋地域市場:機会と予測 (2014〜2020年)

Asia-Pacific In-Vitro Fertilization Services Market - Opportunities and Forecasts, 2014 - 2020

発行 Allied Market Research 商品コード 352278
出版日 ページ情報 英文 132 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
体外受精サービスのアジア太平洋地域市場:機会と予測 (2014〜2020年) Asia-Pacific In-Vitro Fertilization Services Market - Opportunities and Forecasts, 2014 - 2020
出版日: 2016年01月01日 ページ情報: 英文 132 Pages
概要

アジア太平洋地域の体外受精サービス市場は、2014年の19億米ドルから2020年までCAGR10.8%で拡大し、35億米ドルに達すると予測されています。高齢出産、不妊率の上昇、新たな不妊治療ツーリズム先の登場などにより、同市場は今後大きく成長するものとみられています。複数の学術機関は、広範な研究開発活動と、より効果的かつ優れた治療施設の提供を目指しが不妊治療クリニックや病院と連携しています。

当レポートでは、アジア太平洋地域の体外受精サービス市場について調査し、エンドユーザー別、サイクルタイプ別、および国別動向ととともに、2020年までの市場成長見通し、市場に参入する主要企業のプロファイルをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場分析

  • 市場の定義と範囲
  • 概要
  • 促進因子
  • 阻害因子
  • 国別胚移植市場
  • エンドユーザー別肺移植市場
  • 企業プロファイル
    • Thermo Fisher Scientific Inc.
    • EMD Serono, Inc.

第4章 中国市場

  • エンドユーザー別市場
  • サイクルタイプ別市場
  • 促進因子
  • 阻害因子
  • 法的課題、法規制、権限
  • 保険償還シナリオ
  • 企業プロファイル
    • Cook Medical, Inc.
    • Vitrolife AB
    • Centre for Reproductive Medicine
    • Reproductive and genetic Hospital Citic-Xiangya
    • Shenyang Hospital
    • Shandong Provincial Hospital

第5章 インド市場

  • エンドユーザー別市場
  • サイクルタイプ別市場
  • 促進因子
  • 阻害因子
  • 法的課題、法規制、権限
  • 保険償還シナリオ
  • 企業プロファイル
    • Sun Pharmaceutical Industries Ltd.
    • Trivector Origio Scientific Pvt. Ltd
    • Lab IVF Asia Pte. Ltd.
    • LG Life Sciences.
    • Cadila Healthcare Ltd. (Zydus Cadila group)
    • Bourn Hall Clinic
    • Morpheus IVF Fertility Center
    • Southend Fertility and IVF Centre
    • Nova IVI Fertility
    • Bloom Fertility Center
    • Manipal Ankur
    • Cloudnine

第6章 韓国市場

  • エンドユーザー別市場
  • サイクルタイプ別市場
  • 促進因子
  • 阻害因子
  • 法的課題、法規制、権限
  • 保険償還シナリオ
  • 企業プロファイル
    • Cha General Hospital
    • Maria Fertility Hospital

第7章 ニュージーランド市場

  • エンドユーザー別市場
  • サイクルタイプ別市場
  • 促進因子
  • 阻害因子
  • 法的課題、法規制、権限
  • 保険償還シナリオ
  • 企業プロファイル
    • Fertility Associates
    • Fertility Plus
    • Reporomed

第8章 オーストラリア市場

  • エンドユーザー別市場
  • サイクルタイプ別市場
  • 促進因子
  • 阻害因子
  • 法的課題、法規制、権限
  • 保険償還シナリオ
  • 企業プロファイル
    • Genea Biomedx
    • Thermo Fisher Scientific Inc.
    • Virtus Health
    • Monash IVF
    • City Fertility
    • Flinders Fertility

第9章 日本市場

  • エンドユーザー別市場
  • サイクルタイプ別市場
  • 促進因子
  • 阻害因子
  • 法的課題、法規制、権限
  • 保険償還シナリオ
  • 企業プロファイル
    • EMD Serono, Inc.
    • IVFなんばクリニック
    • いわき婦人科
    • 山王病院

第10章 東南アジア市場

  • 東南アジアの肺移植市場
  • シンガポール
  • マレーシア
  • インドネシア
  • タイ
  • フィリピン
  • ベトナム

図表

目次

In-vitro fertilization is an assisted reproductive technology, which involves a series of procedures for treating infertility problems. It involves the fertilization of the ovum in-vitro, followed by implantation of the embryo into a womens uterus. The IVF technology is fast gaining pace in the Asia Pacific region, as the infertility rates are spiraling. In addition, the rapidly rising geriatric population is a major concern for countries with below average birth rates such as, Indonesia, Vietnam, Cambodia and Philippines. Also, the rising trends towards delaying pregnancy has steadily increased in China and many other countries, resulting in aging of the eggs, making it less suitable for fertilization. This in turn, has increased the need of IVF services. Moreover, the commercialization of cost-effective fertility treatments and significant growth in medical tourism across Asia-Pacific would offer lucrative opportunities in future. Furthermore, proactive initiatives for the development of novel IVF technologies would facilitate the dynamic growth of the Asia-Pacific IVF market.

The Asia-Pacific IVF services market was evaluated at $1.9 billion in 2014 and is estimated to garner $3.5 billion by 2020, registering a CAGR of 10.8% during the forecast period 20152020. This market is expected to witness significant growth during the forecast period on account of the delayed pregnancies, rising infertility rates due to dysfunctional lifestyles, environmental pollution, increasing disposable incomes and emergence of newer fertility tourism destinations. In addition, several academic institutions are collaborating with fertility hospitals and clinics to conduct extensive research & development activities, and provide more effective and better treatment facilities. The other factors, namely technological advancements, utilization of intra-cytoplasmic sperm injection (ICSI) technique and growing popularity of donor egg IVF methods would collectively boost the success rates of IVF cycles. However, factors such as high costs associated with the treatment, lack of favorable IVF reimbursement policies and lower health awareness, especially in the underdeveloped Asia-Pacific countries, such as Nepal and Myanmar, are the major factors hampering the market growth. In addition, ethical concerns regarding the parental rights are expected to have a restraining effect on the growth of the market.

The Asia-Pacific IVF services market is segmented on the basis of end users, cycles type and country-wise analysis. Based on the type of cycle performed, the market is categorized into fresh cycle (non-donor), thawed IVF cycle (non-donor) and donor egg IVF cycles. Fresh IVF cycle is the largest revenue-generating segment, owing to increasing preference of IVF for infertility treatment. The end users market is categorized into fertility clinics, hospitals, surgical centers and clinical research institutes. In 2014, fertility clinics were the leading end user segments, accounting for about one-fifths of the overall market share.

Geographically, this market is segmented into India, China, Japan, Vietnam, Korea, Australia, New Zealand, Thailand, Malaysia, Indonesia, Philippines, Singapore, and other Asia-Pacific countries. In terms of revenue, Japan dominates the Asia-Pacific IVF market, owing to the large consumer base, rapid adoption of advanced technologies and availability of skilled workforce. However, the Indian IVF market is anticipated to register a promising CAGR of 14.7% during the forecast period. This is mainly supplemented by factors, such as the rising trend of fertility tourism, favorable regulation of surrogacy and donor services, and wide availability of IVF clinics. Based on number of cycles performed, Japan is the leading country, accounting for a major share of the market and is expected to maintain this trend throughout the forecast period. However, the India IVF market, in terms of number of cycles performed, is anticipated to grow at a promising CAGR of 16.3% during the study period.

KEY MARKET BENEFITS:

This report provides an in-depth analysis of the Asia-Pacific IVF market across seven major countries along with cross sectional analysis of the total number of IVF cycles performed and the total revenue generated during the forecast period.

It includes the strategies adopted by various IVF clinics and hospitals across major countries to capitalize on the latent opportunities in the Asia-Pacific IVF market.

This report comprehensively analyzes the market scenario across different countries in the Asia-Pacific region.

The projections in this report are made by analyzing the current market trends and highlighting the market potential, in terms of value and volume, from 2014 to 2020.

Extensive analysis of the market is conducted by following the key product positioning and monitoring the top contenders.

ASIA-PACIFIC IN-VITRO FERTILIZATION SERVICES MARKET KEY SEGMENTS:

The Asia-Pacific IVF market is segmented on the basis of end users, cycle type and country:

By End Users (Value and Volume)

  • Fertility clinics
  • Hospitals
  • Surgical centers
  • Clinical research institutes

By Cycle Type, (Value and Volume)

  • Fresh cycle (non-donor)
  • Thawed IVF cycle (non-donor)
  • Donor egg IVF cycles

By Cycle Type Country Level Analysis (Value and Volume)

  • India
  • China
  • Japan
  • Australia
  • New Zealand
  • Korea
  • Thailand
  • Singapore
  • Malaysia
  • Indonesia
  • Philippines
  • Vietnam
  • Others

Table of Contents

CHAPTER 1-INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Coverage and limitations
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models
<>CHAPTER 2-EXECUTIVE SUMMARY

CHAPTER 3-ASIA PACIFIC IVF MARKET ANALYSIS

  • 3.1. Market definition and scope
  • 3.2. Overview
  • 3.3. Drivers
    • 3.3.1. Delay in family planning reduces fertility
    • 3.3.2. Decline in birth rate
    • 3.3.3. Emotional problems
  • 3.4. Restraints
  • 3.5. Asia Pacific embryo transfer market by country
  • 3.6. Asia-Pacific fresh embryo transfersby country
  • 3.7. Asia-Pacific frozen embryo transfers by country
  • 3.8. Asia Pacific embryo transfer market by end users
  • 3.9. Asia-Pacific embryo transfer market by cycle type
  • 3.10. Company profile
    • 3.10.1. Thermo Fisher Scientific Inc.
    • 3.10.2. EMD Serono, Inc.

CHAPTER 4-CHINA EMBRYO TRANSFER MARKET

  • 4.1. China embryo transfer market by end users
  • 4.2. China embryo transfer market by cycle type
  • 4.3. Drivers
    • 4.3.1. Increased rate of infertility
    • 4.3.2. Change in lifestyle
  • 4.4. Restraints
    • 4.4.1. Cost of living
  • 4.5. Regulatory issues, legislations and authorities
  • 4.6. Insurance reimbursement scenario
  • 4.7. Company profile
    • 4.7.1. Cook Medical, Inc.
    • 4.7.2. Vitrolife AB
    • 4.7.3. Centre for Reproductive Medicine
    • 4.7.4. Reproductive and genetic Hospital Citic-Xiangya
    • 4.7.5. Shenyang Hospital
    • 4.7.6. Shandong Provincial Hospital

CHAPTER 5-INDIA EMBRYO TRANSFER MARKET

  • 5.1. India embryo transfer market by end users
  • 5.2. India embryo transfer market by cycle type
  • 5.3. Drivers
  • 5.4. Restraints
  • 5.5. Regulatory issues, legislations and authorities
  • 5.6. Insurance reimbursement scenario
  • 5.7. Company profile
    • 5.7.1. Sun Pharmaceutical Industries Ltd.
    • 5.7.2. Trivector Origio Scientific Pvt. Ltd
    • 5.7.3. Lab IVF Asia Pte. Ltd.
    • 5.7.4. LG Life Sciences.
    • 5.7.5. Cadila Healthcare Ltd. (Zydus Cadila group)
    • 5.7.6. Bourn Hall Clinic
    • 5.7.7. Morpheus IVF Fertility Center
    • 5.7.8. Southend Fertility and IVF Centre
    • 5.7.9. Nova IVI Fertility
    • 5.7.10. Bloom Fertility Center
    • 5.7.11. Manipal Ankur
    • 5.7.12. Cloudnine

CHAPTER 6-KOREA EMBRYO TRANSFER MARKET

  • 6.1. Korea embryo transfer market by end users
  • 6.2. Korea embryo transfer market by cycle type
  • 6.3. Drivers
  • 6.4. Restraints
  • 6.5. Regulatory issues, legislations and authorities
  • 6.6. Insurance reimbursement scenario
  • 6.7. Company Profiles
    • 6.7.1. Cha General Hospital
    • 6.7.2. Maria Fertility Hospital

CHAPTER 7-NEW ZEALAND EMBRYO TRANSFER MARKET

  • 7.1. New Zealand embryo transfer market by end users
  • 7.2. New Zealand embryo transfer market by cycle type
  • 7.3. Drivers
  • 7.4. Restraints
  • 7.5. Regulatory issues, legislations and authorities
  • 7.6. Insurance reimbursement scenario
  • 7.7. Company Profiles
    • 7.7.1. Fertility Associates
    • 7.7.2. Fertility Plus
    • 7.7.3. Reporomed

CHAPTER 8-AUSTRALIA EMBRYO TRANSFER MARKET

  • 8.1. Australia embryo transfer market by end users
  • 8.2. Australia embryo transfer market by cycle type
  • 8.3. Drivers
  • 8.4. Restraints
    • 8.4.1. Emotional and physical stress
    • 8.4.2. No guarantee
    • 8.4.3. Surplus embryos
  • 8.5. Regulatory issues, legislations and authorities
    • 8.5.1. Common Law
    • 8.5.2. Legislative responses to IVF
    • 8.5.3. Non-legislative regulation for the practice of IVF
  • 8.6. Insurance reimbursement scenario
  • 8.7. Company profile
    • 8.7.1. Genea Biomedx
    • 8.7.2. Thermo Fisher Scientific Inc.
    • 8.7.3. Virtus Health
    • 8.7.4. Monash IVF
    • 8.7.5. City Fertility
    • 8.7.6. Flinders Fertility

CHAPTER 9-JAPAN EMBRYO TRANSFER MARKET

  • 9.1. Japan embryo transfer market by end users
  • 9.2. Japan embryo transfer market by cycle type
  • 9.3. Drivers
  • 9.4. Restraints
  • 9.5. Regulatory issues, legislations and authorities
  • 9.6. Insurance reimbursement scenario
  • 9.7. Company profile
    • 9.7.1. EMD Serono, Inc.
    • 9.7.2. IVF Namba Clinic
    • 9.7.3. Iwaki Womens Clinic
    • 9.7.4. Sanno Hospital

CHAPTER 10-SOUTH-EAST ASIA EMBRYO TRANSFER MARKET

  • 10.1. South-East Asia embryo transfer market
  • 10.2. Singapore embryo transfer market
    • 10.2.1. Singapore embryo transfer market by end users
    • 10.2.2. Singapore embryo transfer market by cycle type
    • 10.2.3. Drivers
      • 10.2.3.1. Government funding and tax rebates for parents
      • 10.2.3.2. Rising infertility rate
      • 10.2.3.3. Increase in success rate
    • 10.2.4. Restraints
      • 10.2.4.1. High cost of IVF treatment and lower success rate
    • 10.2.5. Regulatory issues, legislations and authorities
    • 10.2.6. Insurance reimbursement scenario
    • 10.2.7. Company profile
      • 10.2.7.1. Irvine Scientific
      • 10.2.7.2. Esco Technologies, Inc.
      • 10.2.7.3. Leica Microsystems Gmbh
    • 10.2.8. Company snapshot
      • 10.2.8.1. NUH IVF Centre
      • 10.2.8.2. Mount Elizabeth Fertility Center
      • 10.2.8.3. Thomson Fertility Centre
      • 10.2.8.4. Raffles Fertility Centre
  • 10.3. Malaysia embryo transfer market
    • 10.3.1. Malaysia embryo transfer market by end users
    • 10.3.2. Malaysia embryo transfer market by cycle type
    • 10.3.3. Drivers
      • 10.3.3.1. Increase in government initiatives
      • 10.3.3.2. Increase in the number of foreign patients
      • 10.3.3.3. Decrease in rate of fertility and growing acceptability of IVF
    • 10.3.4. Restraints
    • 10.3.5. Regulatory issues, legislations and authorities
    • 10.3.6. Insurance reimbursement scenario
    • 10.3.7. Company Profiles
      • 10.3.7.1. Subang Fertility Center Subang Jaya Hospital, Subang
      • 10.3.7.2. Concept Fertility Center
      • 10.3.7.3. TMC Fertility Center
  • 10.4. Indonesia embryo transfer market
    • 10.4.1. Indonesia embryo transfer market by end users
    • 10.4.2. Indonesia embryo transfer market by cycle type
    • 10.4.3. Drivers
      • 10.4.3.1. Increase in disposable income
      • 10.4.3.2. Advances in embryo transfer technology
      • 10.4.3.3. Decline in fertility rate
    • 10.4.4. Restraints
      • 10.4.4.1. Physical and emotional impact due to low success rate
    • 10.4.5. Regulatory issues, legislations and authorities
    • 10.4.6. Insurance reimbursement scenario
    • 10.4.7. Company profiles
      • 10.4.7.1. Morula IVF
      • 10.4.7.2. Yasmin IVF
      • 10.4.7.3. Aster Fertility Clinic
      • 10.4.7.4. Fertility Centre, Siloam Hospitals Surabana
  • 10.5. Philippines embryo transfer market
    • 10.5.1. Philippines embryo transfer market by end users
    • 10.5.2. Philippines embryo transfer market by cycle type
    • 10.5.3. Drivers
      • 10.5.3.1. Improve the replacement population
      • 10.5.3.2. Advancement in technology
    • 10.5.4. Restraints of embryo transfer market in Philippines
    • 10.5.5. Regulatory issues, legislations and authorities
    • 10.5.6. Insurance reimbursement scenario
    • 10.5.7. Company Profiles
      • 10.5.7.1. Victory Art Lab
      • 10.5.7.2. CRM-MIA-Philippines
  • 10.6. Thailand embryo transfer market
    • 10.6.1. Thailand embryo transfer market by end users
    • 10.6.2. Thailand embryo transfer market by cycle type
    • 10.6.3. Drivers
      • 10.6.3.1. Government initiatives
      • 10.6.3.2. Surrogacy is economical as compared to developed countries
      • 10.6.3.3. Boost in medical tourism
    • 10.6.4. Restraints of embryo transfer in Thailand
      • 10.6.4.1. Comparatively low success rate
      • 10.6.4.2. Ethical issues in allowing gender selection
    • 10.6.5. Regulatory issues, legislations and authorities
    • 10.6.6. Insurance reimbursement scenario
    • 10.6.7. Company Profiles
      • 10.6.7.1. Bangkok Fertility Center
      • 10.6.7.2. Siriraj Hospital
      • 10.6.7.3. Ramathibodi Hospital
      • 10.6.7.4. Perfect Woman Institute Piyavate Hospital
      • 10.6.7.5. Jetanin Institute for Assisted Reproduction
  • 10.7. Vietnam embryo transfer market
    • 10.7.1. Vietnam embryo transfer market by end users
    • 10.7.2. Vietnam embryo transfer market by cycle type
    • 10.7.3. Drivers
      • 10.7.3.1. Decline in fertility rate
      • 10.7.3.2. Reasonable cost and good success rate
    • 10.7.4. Restraints of the embryo transfer market in Vietnam
    • 10.7.5. Regulatory issues, legislations and authorities
    • 10.7.6. Insurance reimbursement scenario
    • 10.7.7. Company Profiles
      • 10.7.7.1. IVF Lab Tu Du Hospital Vietnam
      • 10.7.7.2. IVF Van Hanh
      • 10.7.7.3. IVFAS
      • 10.7.7.4. Tu Du - Ho Chi Minh City Vietnam
  • 10.8. Others embryo transfer market
    • 10.8.1. Others embryo transfer market by end users

List of Tables

  • TABLE 1: ASIA PACIFIC IVF CYCLES MARKET VOLUME, BY COUNTRY, 2014 2020 (THOUSAND)
  • TABLE 2: ASIA PACIFIC EMBRYO TRANSFER MARKET VOLUME, BY COUNTRY, 2014 2020 (THOUSAND)
  • TABLE 3: ASIA PACIFIC EMBRYO TRANSFER MARKET REVENUE, BY COUNTRY, 2014 2020 ($MILLION)
  • TABLE 4: ASIA-PACIFIC FRESH EMBRYO TRANSFER MARKET VOLUME, BY COUNTRY, 2014 2020 (THOUSAND)
  • TABLE 5: ASIA-PACIFIC FRESH EMBRYO TRANSFER MARKET REVENUE, BY COUNTRY, 2014 2020 ($MILLION)
  • TABLE 6: ASIA-PACIFIC FROZEN EMBRYO TRANSFER MARKET VOLUME, BY COUNTRY, 2014 2020 (THOUSAND)
  • TABLE 7: ASIA-PACIFIC FROZEN EMBRYO TRANSFER MARKET REVENUE, BY COUNTRY, 2014 2020 ($MILLION)
  • TABLE 8: ASIA PACIFIC EMBRYO TRANSFER MARKET VOLUME, BY END USER, 2014 2020 (THOUSAND)
  • TABLE 9: ASIA PACIFIC EMBRYO TRANSFER MARKET REVENUE, BY END USER, 2014 2020 ($MILLION)
  • TABLE 10: ASIA-PACIFIC EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014-2020 (THOUSAND)
  • TABLE 11: ASIA-PACIFIC EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014-2020 ($MILLION)
  • TABLE 12: THERMO FISHER SCIENTIFIC INC. BUSINESS OVERVIEW
  • TABLE 13: COMPANY SNAPSHOT
  • TABLE 14: EMD SERONO INC BUSINESS OVERVIEW
  • TABLE 15: COMPANY SNAPSHOT
  • TABLE 16: CHINA EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 17: CHINA EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014 2020 ($MILLION)
  • TABLE 18: CHINA EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014 2020 (THOUSAND)
  • TABLE 19: CHINA EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014 2020 ($MILLION)
  • TABLE 20: COOK MEDICAL INC BUSINESS OVERVIEW
  • TABLE 21: COMPANY SNAPSHOT
  • TABLE 22: VITROLIFE AB INC BUSINESS OVERVIEW
  • TABLE 23: COMPANY SNAPSHOT
  • TABLE 24: INDIA EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 25: INDIA EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014 2020 ($MILLION)
  • TABLE 26: INDIA EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014 2020 (THOUSAND)
  • TABLE 27: INDIA EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014 2020 ($MILLION)
  • TABLE 28: SUN PHARMACEUTICAL BUSINESS OVERVIEW
  • TABLE 29: COMPANY SNAPSHOT
  • TABLE 30: TRIVECTOR ORIGIO SCIENTIFIC BUSINESS OVERVIEW
  • TABLE 31: COMPANY SNAPSHOT
  • TABLE 32: LAB IVF ASIA BUSINESS OVERVIEW
  • TABLE 33: COMPANY SNAPSHOT
  • TABLE 34: LG LIFE SCIENCE BUSINESS OVERVIEW
  • TABLE 35: COMPANY SNAPSHOT
  • TABLE 36: CADILA HEALTH CARE BUSINESS OVERVIEW
  • TABLE 37: COMPANY SNAPSHOT
  • TABLE 38: KOREA EMBRYO TRANSFER MARKET VOLUME, BY END USER, 2014-2020 (THOUSAND)
  • TABLE 39: KOREA EMBRYO TRANSFER MARKET REVENUE, BY END USER, 2014-2020 ($MILLION)
  • TABLE 40: KOREA EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014-2020 (THOUSAND)
  • TABLE 41: KOREA EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014-2020 ($MILLION)
  • TABLE 42: NEW ZEALAND EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 43: NEW ZEALAND EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014 2020 ($MILLION)
  • TABLE 44: NEW ZEALAND EMBRYO TRANSFER MARKET, BY CYCLE TYPE, 2014-2020 ($MILLION)
  • TABLE 45: NEW ZEALAND EMBRYO TRANSFER MARKET, BY CYCLE TYPE, 2014-2020 (THOUSAND)
  • TABLE 46: AUSTRALIA EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 47: AUSTRALIA EMBRYO TRANSFERS MARKET REVENUE BY END USERS, 2014 2020 ($MILLION)
  • TABLE 48: AUSTRALIA EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014-2020 (THOUSAND)
  • TABLE 49: AUSTRALIA EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014-2020 ($MILLION)
  • TABLE 50: GENEA BIOMEDX TECHNOLOGIES BUSINESS OVERVIEW
  • TABLE 51: COMPANY SNAPSHOT
  • TABLE 52: THERMO FISHER SCIENTIFIC INC BUSINESS OVERVIEW
  • TABLE 53: COMPANY SNAPSHOT
  • TABLE 54: JAPAN EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 55: JAPAN EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014 2020 ($MILLION)
  • TABLE 56: JAPAN EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014 2020 (THOUSAND)
  • TABLE 57: JAPAN EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014 2020 ($MILLION)
  • TABLE 58: EMD SERONO INC BUSINESS OVERVIEW
  • TABLE 59: COMPANY SNAPSHOT
  • TABLE 60: TOTAL FERTILITY RATE OF SOUTH-EAST ASIA COUNTRY PER THOUSAND, 2015
  • TABLE 61: SOUTH-EAST ASIA EMBRYO TRANSFER MARKET VOLUME, BY COUNTRY, 2014 2020 (THOUSAND)
  • TABLE 62: SOUTH-EAST ASIA EMBRYO TRANSFER MARKET REVENUE, BY COUNTRY, 2014 2020 ($MILLION)
  • TABLE 63: SINGAPORE EMBRYO TRANSFER MARKET VOLUME, BY END USER, 2014 2020 (THOUSAND)
  • TABLE 64: SINGAPORE EMBRYO TRANSFER MARKET REVENUE, BY END USER, 2014 2020 ($MILLION)
  • TABLE 65: SINGAPORE EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014 2020 (THOUSAND)
  • TABLE 66: SINGAPORE EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014 2020 ($MILLION)
  • TABLE 67: IRVINE SCIENTIFIC BUSINESS OVERVIEW
  • TABLE 68: COMPANY SNAPSHOT
  • TABLE 69: ESCO TECHNOLOGIES BUSINESS OVERVIEW
  • TABLE 70: COMPANY SNAPSHOT
  • TABLE 71: LEICA MICROSYSTEMS GMBH BUSINESS OVERVIEW
  • TABLE 72: MALAYSIA EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 73: MALAYSIA EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014 2020 ($MILLION)
  • TABLE 74: MALAYSIA EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014 2020 (THOUSAND)
  • TABLE 75: MALAYSIA EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014 2020 ($MILLION)
  • TABLE 76: INDONESIA EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 77: INDONESIA EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014 2020 ($MILLION)
  • TABLE 78: INDONESIA EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014 2020 (THOUSAND)
  • TABLE 79: INDONESIA EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014 2020 ($MILLION)
  • TABLE 80: PHILIPPINES EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 81: PHILIPPINES EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014 2020 ($MILLION)
  • TABLE 82: PHILIPPINES EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014 2020 (THOUSAND)
  • TABLE 83: PHILIPPINES EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014 2020 ($MILLION)
  • TABLE 84: THAILAND EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 85: THAILAND EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014 2020 ($MILLION)
  • TABLE 86: THAILAND EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014 2020 (THOUSAND)
  • TABLE 87: THAILAND EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014 2020 ($MILLION)
  • TABLE 88: VIETNAM EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014 2020 (THOUSAND)
  • TABLE 89: VIETNAM EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014 2020 ($MILLION)
  • TABLE 90: VIETNAM EMBRYO TRANSFER MARKET VOLUME, BY CYCLE TYPE, 2014 2020 (THOUSAND)
  • TABLE 91: VIETNAM EMBRYO TRANSFER MARKET REVENUE, BY CYCLE TYPE, 2014 2020 ($MILLION)
  • TABLE 92: OTHERS EMBRYO TRANSFER MARKET VOLUME, BY END USERS, 2014-2020 (THOUSAND)
  • TABLE 93: OTHERS EMBRYO TRANSFER MARKET REVENUE, BY END USERS, 2014-2020 ($MILLION)
  • TABLE 94: EMBRYO TRANSFER COST PER CYCLE BY COUNTRY (2014)

List of Figures

  • FIG. 1: PERCENTAGE OF PEOPLE WHO PERCEIVED VARIOUS INFERTILITY REASONS (SINGAPORE, THAILAND, INDONESIA AND CHINA)
  • FIG. 2: CHINA FERTILITY RATE (CHILDREN BORN/WOMEN) (2010-2014)
  • FIG. 3: INDIA TOTAL FERTILITY RATE (CHILDREN BORN/ WOMEN) (2010-2014)
  • FIG. 4: SOUTH KOREA TOTAL FERTILITY RATE (CHILDREN BORN/WOMEN) (2010-2014)
  • FIG. 5: NEW ZEALAND TOTAL FERTILITY RATE (CHILDREN BORN/ WOMEN) (2010-2014)
  • FIG. 6: AUSTRALIA TOTAL FERTILITY RATE (CHILDREN BORN/ WOMEN) (2010-2014)
  • FIG. 7: JAPAN TOTAL FERTILITY RATE (CHILDREN BORN/ WOMEN) (2010-2014)
  • FIG. 8: SINGAPORE FERTILITY RATE CHILD BORN/WOMEN (2010-2014)
  • FIG. 9: MALAYSIA FERTILITY RATE CHILD BORN/WOMEN (2010-2014)
  • FIG. 10: INDONESIA FERTILITY RATE CHILD BORN/WOMEN (2010-2014)
  • FIG. 11: PHILIPPINES FERTILITY RATE CHILD BORN/WOMEN (2014-2020)
  • FIG. 12: THAILAND FERTILITY RATE CHILD BORN/WOMEN (2014-2020)
  • FIG. 13: VIETNAM FERTILITY RATE CHILD BORN/WOMEN (2014-2020)
Back to Top